JP5485897B2 - 抗体−薬物複合体の併用療法 - Google Patents

抗体−薬物複合体の併用療法 Download PDF

Info

Publication number
JP5485897B2
JP5485897B2 JP2010529007A JP2010529007A JP5485897B2 JP 5485897 B2 JP5485897 B2 JP 5485897B2 JP 2010529007 A JP2010529007 A JP 2010529007A JP 2010529007 A JP2010529007 A JP 2010529007A JP 5485897 B2 JP5485897 B2 JP 5485897B2
Authority
JP
Japan
Prior art keywords
antibody
alkyl
alkenyl
alkynyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010529007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500582A (ja
JP2011500582A5 (cg-RX-API-DMAC7.html
Inventor
オフラゾグル，エゾゲリン
シーバーズ，エリック
ガーバー，ハンス−ピーター
Original Assignee
シアトル ジェネティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティクス，インコーポレーテッド filed Critical シアトル ジェネティクス，インコーポレーテッド
Publication of JP2011500582A publication Critical patent/JP2011500582A/ja
Publication of JP2011500582A5 publication Critical patent/JP2011500582A5/ja
Application granted granted Critical
Publication of JP5485897B2 publication Critical patent/JP5485897B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2010529007A 2007-10-12 2008-10-08 抗体−薬物複合体の併用療法 Expired - Fee Related JP5485897B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97959407P 2007-10-12 2007-10-12
US60/979,594 2007-10-12
US2766808P 2008-02-11 2008-02-11
US61/027,668 2008-02-11
US4064108P 2008-03-28 2008-03-28
US61/040,641 2008-03-28
PCT/US2008/079224 WO2009048967A1 (en) 2007-10-12 2008-10-08 Combination therapy with antibody-drug conjugates

Publications (3)

Publication Number Publication Date
JP2011500582A JP2011500582A (ja) 2011-01-06
JP2011500582A5 JP2011500582A5 (cg-RX-API-DMAC7.html) 2011-11-10
JP5485897B2 true JP5485897B2 (ja) 2014-05-07

Family

ID=40549535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010529007A Expired - Fee Related JP5485897B2 (ja) 2007-10-12 2008-10-08 抗体−薬物複合体の併用療法

Country Status (13)

Country Link
US (2) US8263083B2 (cg-RX-API-DMAC7.html)
EP (1) EP2211885B1 (cg-RX-API-DMAC7.html)
JP (1) JP5485897B2 (cg-RX-API-DMAC7.html)
KR (1) KR101641345B1 (cg-RX-API-DMAC7.html)
CN (1) CN101969970B (cg-RX-API-DMAC7.html)
AU (1) AU2008310908B2 (cg-RX-API-DMAC7.html)
CA (1) CA2699090C (cg-RX-API-DMAC7.html)
EA (1) EA020696B1 (cg-RX-API-DMAC7.html)
IL (1) IL204851A (cg-RX-API-DMAC7.html)
MX (1) MX2010003977A (cg-RX-API-DMAC7.html)
NZ (1) NZ584552A (cg-RX-API-DMAC7.html)
WO (1) WO2009048967A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002428B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
KR101641345B1 (ko) 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
US9211319B2 (en) * 2009-01-09 2015-12-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
US8758758B1 (en) * 2010-01-08 2014-06-24 Seattle Genetics, Inc. Post-relapse treatment of CD30 expressing lymphomas
JP6046494B2 (ja) * 2010-02-08 2016-12-14 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
CA2848520C (en) 2011-09-29 2019-11-26 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
MX375987B (es) * 2011-10-14 2025-03-07 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
ES2657014T3 (es) 2011-11-17 2018-03-01 Pfizer Inc. Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
CN104254778A (zh) * 2012-02-10 2014-12-31 西雅图遗传学公司 Cd30+癌症的检测和治疗
MX2015005810A (es) 2012-11-07 2015-09-23 Pfizer Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP2020536916A (ja) * 2017-10-11 2020-12-17 シアトル ジェネティクス，インコーポレイティド 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
WO2019075188A1 (en) * 2017-10-13 2019-04-18 Seattle Genetics, Inc. MODULATION OF IMMUNE RESPONSE USING CONJUGATES ANTIBODY-MEDICINE
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP7430643B2 (ja) * 2018-04-06 2024-02-13 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
MY198034A (en) * 2018-12-21 2023-07-27 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
AU2020356955A1 (en) * 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
AU2021212193A1 (en) * 2020-01-31 2022-09-08 Celgene Corporation Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN119490595B (zh) * 2023-08-15 2025-11-18 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7090843B1 (en) * 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
WO2007044616A2 (en) * 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
WO2008103916A2 (en) 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
KR101641345B1 (ko) 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법

Also Published As

Publication number Publication date
JP2011500582A (ja) 2011-01-06
US20100215671A1 (en) 2010-08-26
CA2699090A1 (en) 2009-04-16
EP2211885A1 (en) 2010-08-04
CA2699090C (en) 2016-02-02
CN101969970B (zh) 2014-10-15
US20130022627A1 (en) 2013-01-24
KR20100087288A (ko) 2010-08-04
KR101641345B1 (ko) 2016-07-20
IL204851A (en) 2016-08-31
CN101969970A (zh) 2011-02-09
IL204851A0 (en) 2010-11-30
NZ584552A (en) 2012-07-27
US8470329B2 (en) 2013-06-25
EA020696B1 (ru) 2015-01-30
WO2009048967A1 (en) 2009-04-16
AU2008310908B2 (en) 2014-01-09
HK1151727A1 (zh) 2012-02-10
MX2010003977A (es) 2010-04-30
EP2211885A4 (en) 2012-09-26
US8263083B2 (en) 2012-09-11
AU2008310908A1 (en) 2009-04-16
EP2211885B1 (en) 2015-07-29
ZA201002428B (en) 2011-06-29
EA201070463A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
JP5485897B2 (ja) 抗体−薬物複合体の併用療法
CN106563128B (zh) 以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
US9919061B2 (en) CD19 binding agents and uses thereof
US20110070248A1 (en) Dr5 ligand drug conjugates
US20150079114A1 (en) Dr5 ligand drug conjugates
JP2007500236A (ja) 組換え抗ｃｄ３０抗体とその使用
TWI873167B (zh) 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症
HK1151727B (en) Combination therapy with antibody-drug conjugates

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20110112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140220

R150 Certificate of patent or registration of utility model

Ref document number: 5485897

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees